Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer.

Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.

Radioimmunotherapy in mantle cell lymphoma.

Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.

Expanding the tools available for direct ortho cupration--targeting lithium phosphidocuprates.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Tetanus toxoid reactive lymphadenopathy masquerading as T-cell lymphoma.

Brentuximab vedotin in anaplastic large cell lymphoma.

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

Endoscopic evaluation of the navicular bursa: observations, treatment and outcome in 92 cases with identified pathology.